Identifying weaknesses in a type of cancer linked to genetic mutations.
Genome-wide synthetic lethal screening for vulnerabilities in a cell model of succinate dehydrogenase-loss paraganglioma
This study is looking at a type of inherited cancer called familial paraganglioma to find out how certain genetic weaknesses in cancer cells can help us develop new treatments that specifically target those weaknesses.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10750986 on NIH RePORTER |
What this research studies
This research investigates familial paraganglioma, a neuroendocrine cancer caused by inherited mutations that affect a key enzyme in energy production. By using a genome-wide synthetic lethal screening approach, the study aims to uncover specific genetic vulnerabilities in cancer cells that have lost succinate dehydrogenase function. This could lead to the identification of targeted therapies that exploit these weaknesses. The research employs advanced techniques such as CRISPR to systematically analyze gene interactions and their effects on cancer cell survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with familial paraganglioma or those with genetic predispositions to this type of cancer.
Not a fit: Patients without succinate dehydrogenase-loss paraganglioma or those with other unrelated cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted treatments for patients with succinate dehydrogenase-loss paraganglioma.
How similar studies have performed: Previous research has successfully utilized similar genome-wide screening approaches to identify vulnerabilities in other cancer types, suggesting potential for success in this study.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Maher, Louis James — Mayo Clinic Rochester
- Study coordinator: Maher, Louis James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.